These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 22709009)
1. 1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 2): action in other targets and antitargets. Carosati E; Ioan P; Micucci M; Broccatelli F; Cruciani G; Zhorov BS; Chiarini A; Budriesi R Curr Med Chem; 2012; 19(25):4306-23. PubMed ID: 22709009 [TBL] [Abstract][Full Text] [Related]
2. 1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 1): action in ion channels and GPCRs. Ioan P; Carosati E; Micucci M; Cruciani G; Broccatelli F; Zhorov BS; Chiarini A; Budriesi R Curr Med Chem; 2011; 18(32):4901-22. PubMed ID: 22050742 [TBL] [Abstract][Full Text] [Related]
3. Dihydropyridines: evaluation of their current and future pharmacological applications. Edraki N; Mehdipour AR; Khoshneviszadeh M; Miri R Drug Discov Today; 2009 Nov; 14(21-22):1058-66. PubMed ID: 19729074 [TBL] [Abstract][Full Text] [Related]
4. Atypical 1,4-dihydropyridine derivatives, an approach to neuroprotection and memory enhancement. Klusa V Pharmacol Res; 2016 Nov; 113(Pt B):754-759. PubMed ID: 27234899 [TBL] [Abstract][Full Text] [Related]
5. Synthesis of new N3-substituted dihydropyrimidine derivatives as L-/T- type calcium channel blockers. Teleb M; Zhang FX; Farghaly AM; Aboul Wafa OM; Fronczek FR; Zamponi GW; Fahmy H Eur J Med Chem; 2017 Jul; 134():52-61. PubMed ID: 28399450 [TBL] [Abstract][Full Text] [Related]
6. Binding mechanism investigations guiding the synthesis of novel condensed 1,4-dihydropyridine derivatives with L-/T-type calcium channel blocking activity. Schaller D; Gündüz MG; Zhang FX; Zamponi GW; Wolber G Eur J Med Chem; 2018 Jul; 155():1-12. PubMed ID: 29843108 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of some novel N-aryl-1,4-dihydropyridines as potential antitubercular agents. Trivedi AR; Dodiya DK; Dholariya BH; Kataria VB; Bhuva VR; Shah VH Bioorg Med Chem Lett; 2011 Sep; 21(18):5181-3. PubMed ID: 21824772 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and 3D-QSAR studies of novel 1,4-dihydropyridines as TGFβ/Smad inhibitors. Längle D; Marquardt V; Heider E; Vigante B; Duburs G; Luntena I; Flötgen D; Golz C; Strohmann C; Koch O; Schade D Eur J Med Chem; 2015 May; 95():249-66. PubMed ID: 25817775 [TBL] [Abstract][Full Text] [Related]
9. Polyphenolic antioxidants mimic the effects of 1,4-dihydropyridines on neurotensin receptor function in PC3 cells. Carraway RE; Hassan S; Cochrane DE J Pharmacol Exp Ther; 2004 Apr; 309(1):92-101. PubMed ID: 14718582 [TBL] [Abstract][Full Text] [Related]
10. Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells. Shekari F; Sadeghpour H; Javidnia K; Saso L; Nazari F; Firuzi O; Miri R Eur J Pharmacol; 2015 Jan; 746():233-44. PubMed ID: 25445037 [TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Biological Evaluation of 1,4-dihydropyridine Derivatives as Potent Antitubercular Agents. Desai NC; Trivedi AR; Somani HC; Bhatt KA Chem Biol Drug Des; 2015 Sep; 86(3):370-7. PubMed ID: 25534154 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Ogihara T; Kano T; Kakinuma C Arzneimittelforschung; 2009; 59(6):283-8. PubMed ID: 19634509 [TBL] [Abstract][Full Text] [Related]
13. Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets. Hudson SA; McLean KJ; Munro AW; Abell C Biochem Soc Trans; 2012 Jun; 40(3):573-9. PubMed ID: 22616869 [TBL] [Abstract][Full Text] [Related]
14. 1,4-Dihydropyridine: A Dependable Heterocyclic Ring with the Promising and the Most Anticipable Therapeutic Effects. Mishra AP; Bajpai A; Rai AK Mini Rev Med Chem; 2019; 19(15):1219-1254. PubMed ID: 31735158 [TBL] [Abstract][Full Text] [Related]
15. Vascular effects of calcium channel antagonists: new evidence. Richard S Drugs; 2005; 65 Suppl 2():1-10. PubMed ID: 16398057 [TBL] [Abstract][Full Text] [Related]
16. Dihydropyridine action on voltage-dependent potassium channels expressed in Xenopus oocytes. Avdonin V; Shibata EF; Hoshi T J Gen Physiol; 1997 Feb; 109(2):169-80. PubMed ID: 9041446 [TBL] [Abstract][Full Text] [Related]
17. Docking and QSAR Studies of 1,4-Dihydropyridine Derivatives as Anti- Cancer Agent. Mollazadeh S; Shamsara J; Iman M; Hadizadeh F Recent Pat Anticancer Drug Discov; 2017; 12(2):174-185. PubMed ID: 28137213 [TBL] [Abstract][Full Text] [Related]
18. 1, 4-Dihydropyridines: a class of pharmacologically important molecules. Khedkar SA; Auti PB Mini Rev Med Chem; 2014; 14(3):282-90. PubMed ID: 24251802 [TBL] [Abstract][Full Text] [Related]
19. [Interaction of 1,4-dihydropyridines with ion channels]. Veizerová L; Svetlík J; Kettmann V Ceska Slov Farm; 2008 Apr; 57(2):58-62. PubMed ID: 18578414 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]